MER769 / Merida Biosciences - LARVOL DELTA

Eli Lilly’s (LLY) acquisition spree continued after the pharmaceutical behemoth agreed to acquire Merida Biosciences for up to $2.875 billion in cash, in a bid to strengthen its autoimmune and allergic diseases portfolio (Yahoo Finance) - "If the deal goes through, it would mark Lilly's 13th acquisition in 2026. The transaction is expected to close in the fourth quarter....Merida's lead drug, MER511, is in Phase 1 development for Graves' disease, an autoimmune disease related to the thyroid gland as well as thyroid eye disease....Merida is also developing MER769 for food allergies, asthma and chronic spontaneous urticaria, a type of skin disease."

M&A • Asthma • Chronic Spontaneous Urticaria • Food Hypersensitivity • Grave’s Disease • Immunology • Thyroid Eye Disease